Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 29, 2008

View Archived Issues

Genome-wide analysis approach potentially useful to identify predictors of response to MS therapy

Studies identify candidate genes for SLE

Cannabidiol arrests onset and progression of autoimmune diabetes in mice

Recent patents report novel analgesic agents

Arena, Merck & Co. initiate phase I niacin receptor agonist trial; MK-0354 development discontinued

New antidiabetic agents described in patent literature

EMEA issues opinion on safety of Gardasil

Lenalidomide approved in Australia and Canada, receives negative opinion in Europe

Positive results reported from phase III SERENE trial of Rituxan in RA

Non-binding CHMP opinion states mifamurtide provides possible survival benefit

Novel treatment option for lipoprotein disorders disclosed in recent Roche patent

Wilex successfully completes phase I study with uPA inhibitor WX-UK1 in advanced solid tumors

TransTech acquires three metabolic disorder programs from Novo Nordisk

Amgen reports positive results from study of denosumab in osteoporosis

Roche reports positive results from phase III CLL8 trial of MabThera for CLL

Successful gene transfer via lumbar puncture alleviates chronic pain in rats

Quantum Genomics and INSERM to codevelop QGC-002 for stroke and cardiac ischemia

Pfizer engages ApoCell to support phase I clinical trial of novel cancer drug

Lower strength Kaletra and Aluvia receive positive EMEA opinions

Nexavar approved in Japan for advanced renal cell carcinoma

Synta and GlaxoSmithKline obtain FDA orphan drug status for elesclomol

Asahi Kasei obtains approval for recombinant thrombomodulin alpha

Gilead Sciences reviews Q4 and full-year 2007 developments

Pfizer Japan's Champix approved for manufacturing and marketing in Japan

Europe authorizes expanded use of The Medicines Company's Angiox in ACS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...